# Gemma Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gemma-biotherapeutics

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.gemmabiotx.com/
- Total disclosed funding: $34M
- Latest round: Seed (Dec 23, 2024)
- Investors on record: 4

## About

Founded in 2024 and based in Pennsylvania, US, Gemma Biotherapeutics, Inc., aka GemmaBio is dedicated to creating advanced gene therapies tailored to rare inherited conditions. The company was founded by its CEO, James M. Wilson. In December 2024, GemmaBio raised USD 34 million in seed funding co-led by Double Point Ventures, Bioluminescence Ventures, Earlybird Venture Capital, and Savanne Life Sciences.

The company’s core offerings revolve around its proprietary adeno-associated virus (AAV) vectors, which have been engineered for gene transfer. These therapies are designed to treat a range of conditions, including cystic fibrosis, dyslipidemias, various neurologic disorders, and liver metabolic diseases, thereby targeting unmet medical needs within marginalized populations. The firm collaborates with Franklin Biolabs to expedite the research and delivery of these therapeutics, which are intended for global distribution, ensuring access for patients worldwide.

GemmaBio's revenue model is primarily based on partnerships and collaborations within the biotechnology and pharmaceutical sectors. Revenue is generated through licensing agreements, research collaborations, and potentially revenue-sharing arrangements related to the commercialization of its gene therapies.

The organization plans to use the December 2024 funding to accelerate its gene therapy initiatives, drive expansion, and support programs.

## Funding rounds

- Seed, Dec 23, 2024, $34M — Earlybird, Bioluminescence Ventures, Double Point Ventures, Savannah Life Sciences

## Investors

- Earlybird (https://capitalatlas.ai/funds/earlybird) — Seed
- Bioluminescence Ventures (https://capitalatlas.ai/funds/bioluminescence-ventures) — Seed
- Double Point Ventures (https://capitalatlas.ai/funds/double-point-ventures) — Seed
- Savannah Life Sciences — Seed